Skip to content

Analgesic Efficacy of Blocking Nerve to Vastus Lateralis Muscle Versus Lateral Femoral Cutaneous Nerve After Knee Surgeries

Analgesic Efficacy of Blocking Nerve to Vastus Lateralis Muscle Versus Lateral Femoral Cutaneous Nerve After Knee Surgeries: A Randomized Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06809842
Enrollment
80
Registered
2025-02-05
Start date
2025-02-05
Completion date
2025-07-30
Last updated
2025-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Vastus Lateralis Nerve Block, Lateral Femoral Cutaneous Nerve Block, Knee Surgeries

Brief summary

This study aims to compare the analgesic efficacy and functional outcomes of blocking the nerve to the vastus lateralis (NVL) muscle versus the lateral femoral cutaneous nerve (LFCN).

Detailed description

Knee surgeries are associated with significant postoperative pain, which can impede early mobilization and prolong recovery. Recent advancements in ultrasound-guided regional anesthesia have enabled more targeted nerve blocks, such as the blockade of the nerve to the vastus lateralis (NVL) and the lateral femoral cutaneous nerve (LFCN)

Interventions

DRUGVastus lateralis nerve block

Patients received vastus lateralis nerve block with 5 ml of bupivacaine 0.5%.

Patients received lateral femoral cutaneous nerve block with 5 ml of bupivacaine 0.5%.

Sponsors

Kafrelsheikh University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status from I to III. * Underwent knee surgeries under spinal anesthesia.

Exclusion criteria

* Pregnancy. * Coagulopathy. * Neuromuscular disorders. * Hematological disorders. * Mental disorders. * History of multiple traumas or anesthesia drug allergies. * Local skin infection at the block site. * Body mass index (BMI) greater than 40. * Opioid analgesics or abusing opioids.

Design outcomes

Primary

MeasureTime frameDescription
Degree of pain24 hours postoperativelyEach patient will be instructed about postoperative pain assessment using the numeric rating scale (NRS) score (0 represents no pain while 10 represents the worst pain imaginable). NRS assessments will be conducted at the post-anesthesia care unit (PACU) and at 2, 4, 6, 12, 18, and 24 hours postoperatively.

Secondary

MeasureTime frameDescription
Total morphine consumption24 hours postoperativelyIf the numeric rating scale (NRS) exceeded 3, rescue analgesia in the form of a 3 mg morphine bolus will be administered, to be repeated after 30 minutes if the pain persisted until the NRS dropped below 4.
Block performance timeIntraoperativelyThe block performance time will be recorded from the placement of the ultrasound probe to the removal of the needle after the injection of local anaesthetic.
Time to first request for analgesia24 hours postoperativelyThe time to first request for analgesia will be recorded from the end of surgery till the first dose of morphine is administered.
Length of hospital stayTill the discharge from hospital (Up to one week).Length of hospital stay will be recorded from admission till discharge from the hospital.
Incidence of adverse events24 hours postoperativelyIncidence of adverse events such as postoperative nausea and vomiting (PONV), respiratory depression, and local anesthetic (LA) toxicity will be recorded.
Degree of patient satisfaction24 hours postoperativelyThe degree of patient satisfaction will be measured using a 5-point Likert scale (1 = extremely dissatisfied, 2 = unsatisfied, 3 = neutral, 4 = satisfied, 5 = extremely satisfied).

Countries

Egypt

Contacts

Primary ContactSherif K Arafa, MD
Sherifhafez1980@gmail.com00201005714014

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026